Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling-The CATCH experience.

ABSTRACT: CATCH is a prospective precision oncology registry trial that exploits whole-genome/exome- and RNA-sequencing to enable actionable biomarker detection in metastatic breast cancer (mBC) patients of any subtype. We herein report long-term follow-up of the first 558 patients consecutively recruited into CATCH in a monocentric setting between June 2017 and October 2021. Main outcome measures were the rate of implementation of molecular tumor board (MTB) recommended treatments and treatment response as assessed by disease control rate, objective response rate and PFS ratio. Out of the recruited patients, 412 (54.9% HR+/HER2-, 31.3% TNBC, 6.8% HR-/HER2+ and 7.0% HR+/HER2+) were reviewed in the MTB. An appropriate molecularly guided anti-cancer treatment as recommended by MTB was implemented in 1

SUBMITTER: Hlevnjak M 

PROVIDER: S-EPMC12811195 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature